Biomissile
Latest round
- Series B
Last raised
- May 2023
Total raised
- $54M
Investors
- 2
About Biomissile
Established in 2020 and based in Suzhou, China, Biomissile is a biopharmaceutical company that focuses on the development of innovative biomolecular drugs. The company's core team has more than 20 years of experience in the development of biologically innovative drugs. The company has established several fully human rapid antibody discovery and optimization platforms, including a fully human nanobody (UDABTM) and a bispecific antibody platform (UDAB-MTM), as well as phage, yeast, and mammalian cell display platforms.
Who invested in Biomissile
2 investors across 2 rounds
See all investors in Biomissile
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Biomissile
Who invested in Biomissile?
Biomissile has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Biomissile raised?
Biomissile has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Biomissile last raise money?
Biomissile's most recent round on record is a Series B, in May 2023.
What does Biomissile do?
Established in 2020 and based in Suzhou, China, Biomissile is a biopharmaceutical company that focuses on the development of innovative biomolecular drugs.
Where is Biomissile headquartered?
Biomissile is headquartered in Suzhou, China.
Which VCs invest in companies like Biomissile?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Biomissile's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Biomissile? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.